Current and Emerging Anti-Obesity Drugs Including GLP-1 Agonists, Leptin Analogs, and MC4R Agonists

Comprehensive narrative review of anti-obesity medications covering clinical trial data, efficacy, FDA-approved indications, contraindications, and serious side effects. Drug classes reviewed include lipase inhibitors, GLP-1 receptor agonists, leptin analogs, and MC4R agonists.

Obesity affects over a third of US adults and is a leading cause of preventable death. While GLP-1 drugs have revolutionized treatment for common obesity, patients with genetic forms of obesity have had limited options. The emergence of targeted peptide therapies like leptin analogs (metreleptin) and MC4R agonists (setmelanotide) represents a shift toward precision medicine in obesity — matching the right drug to the right patient based on their underlying biology.

This review captures a pivotal moment in obesity pharmacotherapy: the transition from one-size-fits-all approaches to targeted therapies based on underlying biology. The peptide-based drug classes discussed — GLP-1 agonists, leptin analogs, and MC4R agonists — represent the leading edge of this shift. As genetic testing becomes more accessible and new multi-target peptide drugs enter development, the ability to match patients with the most effective peptide-based therapy will increasingly define obesity treatment.

Published in Cureus (a community-driven journal), which may have less rigorous peer review than top-tier journals. The review may not capture the latest developments, particularly around tirzepatide and newer pipeline drugs. The coverage of emerging therapies is necessarily based on limited clinical trial data. Head-to-head comparisons between drug classes were not available for all agents discussed.